Krystal Biotech, Inc. (KRYS)
Krystal Biotech develops and makes gene therapies, including VYJUVEK, a topical treatment for a rare inherited skin disease. It last closed at $298.55 on Nov 17, up 0.22% on the day. The average 12-month price target from 6 analysts is $394.83 (+32.3% from the last close), with a high of $441.00 and a low of $361.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in KRYS, 50% of them bullish and 50% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From KRYS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 6 analysts who set a price target on KRYS in the past 90 days. The average target is $394.83, with a high of $441.00 and a low of $361.00, compared with the last close of $298.55.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 3 | Citigroup | Target raised | Buy | $386 → $412 |
| Nov 3 | TD Cowen | Target lowered | Buy | $403 → $380 |
| Nov 3 | RBC Capital | Target lowered | Buy | $400 → $375 |
| Oct 15 | HC Wainwright & Co. | Target raised | Buy | $221 → $361 |
| Sep 25 | HC Wainwright & Co. | Maintained | Buy | $221 |
Technical Analysis
The stock is 4% below its 20 day and 9% below its 50 day average. It is 4% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the Pivot at $297.85, and the nearest resistance the Pivot R1 at $300.64.
| RSI (14) | 39.62 | Weak, oversold below 30 | Neutral |
| MACD | -7.03 | Below its signal line | Bearish |
| Stochastic | 37.4 | Middle of its range | Neutral |
| ADX (14) | 19.1 | No clear trend | |
| Williams %R | -66.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -99.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −2.1% | Change over 10 sessions | Bearish |
| ATR (14) | $10.58 | Typical daily range, 3.5% of price |
| RSI (14) | 44.01 | Middle of its range | Neutral |
| MACD | 1.00 | Below its signal line | Bearish |
| Stochastic | 21.9 | Middle of its range | Neutral |
| ADX (14) | 20.3 | Weak trend | |
| Williams %R | -81.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -143.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −14.0% | Change over 10 sessions | Bearish |
| ATR (14) | $24.69 | Typical daily range, 8.3% of price |
What happened before
See how KRYS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How KRYS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in KRYS in the last 90 days.
KRYS Institutional Ownership
Full report →- ▲256 buying vs 177 selling
- ▼Held by funds -4.4 pts
- ▲Funds holding +16
- ▲Superinvestors: 3 added, 0 cut
- ▼Put/call 2.02 to 3.30
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 442 | 426 | +3.8% |
| In funds' top 10 | 9 | 12 | −25.0% |
| Held by funds | 97.9% | 102.2% | −4.4 pts |
| New / increased | 76 / 180 | 91 / 175 | −3.8% |
| Reduced / sold out | 122 / 55 | 110 / 37 | +20.4% |
| Put/call ratio | 3.30 | 2.02 | +63.8% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRYS is in one of them and how their past KRYS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered KRYS in an article yet. Here's the latest on the wider market.
KRYS Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $100K – $250K | Jul 24, 2026 | Sep 22, 2026 | 60 d |
| Donald J TrumpExecutive branch | Sell | $15K – $50K | May 15, 2026 | Jul 1, 2026 | 47 d |
| Christopher JacobsR · NY | Buy | $1K – $15K | Dec 12, 2022 | Jan 20, 2023 | 39 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Krystal Biotech
Krystal Biotech is a biotechnology company based in Pittsburgh, Pennsylvania, that develops and manufactures gene therapies. Its platform uses an engineered herpes simplex virus to deliver therapeutic genes to target cells. Its approved product, VYJUVEK, is applied directly to the skin to treat dystrophic epidermolysis bullosa, a rare inherited skin disease, and is sold in the United States, Europe and Japan. The company also has clinical stage candidates for other rare diseases.
- Headquarters
- Pittsburgh, PA




